Can I Take Ashwagandha with Sermorelin? A Women's Health Guide

What Sermorelin Does in the Female Body

Sermorelin acetate is a synthetic 29-amino-acid analogue of growth hormone-releasing hormone (GHRH). It binds to GHRH receptors in the pituitary and prompts the gland to secrete growth hormone (GH) in a pulsatile pattern that closely mirrors the body's natural rhythm. This is different from injecting recombinant human GH directly: sermorelin preserves the negative-feedback loop through somatostatin, which makes runaway GH excess less likely.

The FDA approved sermorelin (Geref) for GH deficiency in children, but that approval was withdrawn for commercial reasons in 2008. Today, compounding pharmacies dispense it under 503A regulations for adults diagnosed with GH deficiency or age-related GH decline. Its legal status for general anti-aging use is a grey area, and the FDA has noted concerns about compounded peptides including sermorelin.

Why Women's GH Physiology Is Different

GH secretion in women is not the same as in men. Women have higher baseline GH pulse amplitude, secrete roughly twice the daily GH mass as men of the same age, and are more sensitive to the GH-suppressing effect of elevated estrogen [1]. After menopause, GH pulse frequency and amplitude drop sharply alongside estrogen, contributing to the visceral fat accumulation, lean mass loss, and fatigue many perimenopausal and postmenopausal women report.

Oral estrogen therapy (but not transdermal) suppresses IGF-1 by about 25-35% by increasing hepatic GH resistance [2]. If you use oral estrogen and your clinician measures IGF-1 to guide sermorelin dosing, your number will read artificially low. Transdermal estradiol does not carry the same IGF-1 suppression, which is one reason The Menopause Society supports transdermal routes for women who also want accurate metabolic monitoring.

Who Gets Prescribed Sermorelin

Most sermorelin prescriptions go to adults with confirmed low IGF-1, significant GH-deficiency symptoms (poor sleep, body composition changes, fatigue), or both. Women most likely to be evaluated include those in perimenopause or postmenopause, women with a history of hypothalamic or pituitary dysfunction, and some women with PCOS whose GH axis is dysregulated. A stimulation test (arginine, GHRH-arginine, or glucagon) is the diagnostic standard, though many concierge and telehealth prescribers rely on IGF-1 alone.

What Ashwagandha Does (and Why It Overlaps with Sermorelin's Targets)

Ashwagandha (Withania somnifera) is a Rasayana adaptogen whose active constituents include withanolide glycosides and alkaloids. It has been studied across several biological pathways that happen to intersect with the same hormonal systems sermorelin influences.

Cortisol and the HPA Axis

The most replicated finding in ashwagandha research is cortisol reduction. A 2019 randomized, double-blind, placebo-controlled trial published in Medicine (Baltimore) found that 240 mg/day of a root extract (KSM-66) reduced serum cortisol by 27.9% vs. 7.9% in the placebo group [3]. This matters for sermorelin because cortisol is a functional GH antagonist. High cortisol blunts pituitary GH release and promotes hepatic GH resistance. Reducing cortisol with ashwagandha could, in theory, make GH secretion more efficient, but it could also make IGF-1 levels rise more than your clinician anticipates from sermorelin alone, complicating dose titration.

Thyroid Hormone Effects

A 2018 pilot RCT in the Journal of Alternative and Complementary Medicine found that 600 mg/day of ashwagandha root extract significantly increased serum T3 (by 41.5%) and T4 (by 19.6%) vs. Placebo in subclinically hypothyroid patients [4]. GH itself stimulates peripheral conversion of T4 to T3, so adding ashwagandha on top of sermorelin could produce an additive increase in thyroid hormone activity. For most euthyroid women this is unlikely to cause a clinical problem, but if you have Hashimoto's thyroiditis, are on levothyroxine, or have marginal thyroid function, your TSH could shift enough to require a dose adjustment.

Testosterone and Androgens

A 2015 Phytotherapy Research study showed that ashwagandha increased testosterone by 17% in healthy men over 8 weeks at 300 mg twice daily [5]. Women's data are much thinner. GH also raises androgen levels in women, partly through stimulation of adrenal androgen secretion and partly through IGF-1 mediated effects on the ovary. Women with PCOS are particularly sensitive here: combining sermorelin with a supplement that may nudge androgens upward could worsen acne, hair loss, or hirsutism. This is a pharmacodynamic overlap that needs to be discussed with your prescriber.

Is the Interaction Pharmacokinetic or Pharmacodynamic?

This distinction matters because it tells you whether the two compounds physically interfere with each other's absorption or metabolism, versus whether they simply push the same biological dial.

No published pharmacokinetic data suggest ashwagandha meaningfully alters sermorelin's absorption or degradation. Sermorelin is administered subcutaneously and broken down by plasma peptidases; it does not rely on CYP450 hepatic enzymes. Ashwagandha's withanolides are primarily metabolized hepatically, but they have not been identified as clinically significant CYP3A4 or CYP2D6 inhibitors at typical supplemental doses [6].

The interaction is pharmacodynamic. Both agents converge on:

• The hypothalamic-pituitary axis (HPA and HPG)
• IGF-1 levels
• Thyroid hormone activity
• Androgen output

Here is a practical framework for thinking about the overlap:

| Biological target | Sermorelin effect | Ashwagandha effect | Net concern | |---|---|---|---| | GH pulse amplitude | Increases | Indirect increase via cortisol reduction | Additive; monitor IGF-1 | | Cortisol | Mild reduction (secondary) | Reduces up to 28% | Additive; watch for fatigue paradox if cortisol drops too low | | TSH / T3 | GH increases T3 via T4 conversion | May increase T3 and T4 | Monitor TSH and free T3 in Hashimoto's or levothyroxine users | | Androgens | Increases DHEA-S, possible testosterone | May increase testosterone | PCOS risk; watch acne and hair | | Fasting insulin | GH can raise fasting glucose | Ashwagandha may improve insulin sensitivity | Opposing; net effect unpredictable without labs |

How Timing and Dose Affect the Equation

Sermorelin is typically injected subcutaneously at bedtime, at doses of 0.2 to 0.3 mg per night, to align with the natural nocturnal GH surge [7]. The GH pulse peaks roughly 60 to 90 minutes after sleep onset.

Ashwagandha has a half-life of approximately 3 to 4 hours for its active withanolides and is commonly taken in the evening as well, because of its cortisol-lowering and sleep-promoting properties. There is no published data suggesting a specific dose-separation window is needed; the interaction is not a binding competition but a hormonal overlap.

A practical approach:

1. Take sermorelin at bedtime as prescribed.
2. If you choose to continue ashwagandha, discuss timing with your clinician. Taking it 2 to 3 hours before sermorelin has no pharmacokinetic rationale but gives you cleaner attribution of any side effect that emerges overnight.
3. Use the lowest effective ashwagandha dose (240 to 300 mg of a standardized root extract) rather than higher doses used in testosterone-focused research.
4. Do not start both at the same time. Introduce one, get baseline labs at 4 to 6 weeks, then add the second if your provider agrees.

Life-Stage Considerations for Women

Reproductive Years (Ages 18 to 40)

If you are menstruating regularly and not trying to conceive, the main concern is androgen excess. Sermorelin raises IGF-1, which stimulates ovarian androgen production. Layer ashwagandha on top and you have two potential androgen-raising inputs. Watch for new or worsening acne, scalp hair thinning, or irregular cycles. If you have PCOS, this combination warrants extra scrutiny: your baseline androgens are likely already elevated, and both agents could amplify that.

Trying to Conceive

Neither sermorelin nor ashwagandha has been studied in women actively trying to conceive, and neither is cleared for fertility treatment. ASRM guidelines advise stopping non-essential medications and supplements before attempting pregnancy [8]. Both should be discontinued at least one full menstrual cycle before attempting conception unless a reproductive endocrinologist has specifically reviewed and approved them.

Perimenopause

This is the life stage where this combination is most commonly pursued. Perimenopausal women often experience declining GH pulsatility, worsening sleep, accelerating lean mass loss, and rising cortisol from the sleep disruption and vasomotor symptoms of the transition. Ashwagandha has modest evidence for improving sleep quality and reducing stress in midlife women; sermorelin addresses the GH axis directly. The combination is clinically logical, but it needs monitoring because thyroid and androgen changes in perimenopause are already volatile.

A 2021 study in Menopause found that perimenopausal women report significantly higher perceived stress and cortisol variability than age-matched premenopausal controls, which is relevant context for ashwagandha's mechanism in this group [9].

Postmenopause

GH deficiency is most clinically relevant after menopause. IGF-1 drops progressively; visceral adiposity accelerates; bone turnover shifts. If you are postmenopausal and on oral estrogen, remember that oral estrogen suppresses IGF-1 independently of sermorelin, so your prescriber needs to interpret your IGF-1 with that in mind. Ashwagandha's thyroid effects deserve extra attention in postmenopausal women, who have a higher baseline prevalence of subclinical hypothyroidism.

Pregnancy, Lactation, and Contraception

Sermorelin is contraindicated in pregnancy. GH axis peptides have not been tested in controlled human pregnancy studies, and animal data show potential risks to fetal development. If you become pregnant while using sermorelin, stop it immediately and contact your obstetric provider.

Ashwagandha is not safe in pregnancy. Traditional Ayurvedic use of ashwagandha includes uterine-stimulating applications, and published case reports and one systematic review have linked high-dose ashwagandha to abortifacient effects [10]. The evidence in humans is limited but the risk signal is sufficient that no clinician should recommend it during pregnancy.

Lactation: No human data exist on sermorelin transfer into breast milk. Because GH-axis peptides could theoretically affect infant growth signaling, the precautionary position is to avoid sermorelin while breastfeeding. Ashwagandha also lacks adequate lactation safety data; the Natural Medicines database rates it as "possibly unsafe" in breastfeeding.

Contraception: If you are of reproductive age and prescribed sermorelin, your prescriber should confirm you are using reliable contraception. Sermorelin is not an FDA-approved contraindication in the manner of isotretinoin, but given the unknown fetal risk profile, reliable contraception is strongly advisable during use.

Who This Combination May Be Right For (and Who Should Avoid It)

May Be Appropriate

• Postmenopausal or perimenopausal women with confirmed low IGF-1 who also have high perceived stress and poor sleep quality
• Women with GH deficiency on a stable sermorelin dose who want to address cortisol-driven sleep disruption with a low-dose adaptogen
• Women without Hashimoto's, PCOS, or active androgen-excess symptoms, after provider review

Use with Caution or Avoid

• Women with PCOS or any androgen-excess condition (acne, hirsutism, female-pattern hair loss)
• Women with Hashimoto's thyroiditis or on levothyroxine, because both agents may shift thyroid hormone levels
• Women on oral estrogen therapy, where IGF-1 interpretation is already complicated
• Anyone pregnant, breastfeeding, or actively trying to conceive
• Women with type 1 or type 2 diabetes: sermorelin raises fasting glucose by opposing insulin action, while ashwagandha may lower it. The net effect is unpredictable and could interfere with glycemic management

What Monitoring Should Look Like

If your provider approves the combination, ask for baseline and 3-month labs including:

• IGF-1 (standardized to age and sex norms)
• Fasting glucose and fasting insulin (or HOMA-IR)
• TSH and free T3 (especially if you have any thyroid history)
• Total and free testosterone plus DHEA-S (especially in reproductive-age women and women with PCOS history)
• A symptom log tracking sleep quality, energy, acne, and cycle regularity

The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults recommends targeting IGF-1 in the mid-normal range for age and sex, not the upper quartile [11]. If your IGF-1 climbs above that range while combining sermorelin with ashwagandha, sermorelin dose reduction, not supplementation changes, is the primary lever.

The Evidence Gap: What We Do Not Know

Women have been under-represented in growth hormone research. Most GH deficiency trials enrolled predominantly male participants, and sermorelin-specific trials in women are sparse. A 1996 multicenter study of sermorelin in adults with GH deficiency found improvements in lean body mass and GH secretion but did not stratify outcomes by sex [12].

No published trial has examined sermorelin combined with ashwagandha in any population, male or female. The reasoning in this article is mechanistic inference from studies of each agent separately. That distinction matters when you are deciding whether the combination is worthwhile: you are making a decision under uncertainty, and your prescriber should be honest with you about that gap.

Ashwagandha's testosterone and thyroid effects were primarily studied in men or in populations with pre-existing hypothyroidism, not in euthyroid perimenopausal women. Extrapolating those findings to your specific situation requires clinical judgment, not just supplement label reading.

Practical Steps Before You Combine Them

1. Tell your sermorelin prescriber you are taking ashwagandha. Do not assume supplement disclosure is unnecessary; the pharmacodynamic overlaps are real.
2. Get baseline labs before starting either agent (IGF-1, TSH, free T3, fasting glucose, testosterone, DHEA-S).
3. If you are perimenopausal or postmenopausal and on hormone therapy, specify the route (oral vs. Transdermal) to your prescriber so IGF-1 interpretation is accurate.
4. Start one agent at a time with at least a 4 to 6 week interval between introductions.
5. Use a standardized ashwagandha extract (KSM-66 or Sensoril are the most studied forms) at 240 to 300 mg/day rather than unstandardized root powder.
6. Repeat labs at 3 months and report new symptoms (acne flare, hair shedding, palpitations, cycle changes) promptly.

Your prescriber can lower the sermorelin dose if IGF-1 rises above the mid-normal range for your age and sex; the Endocrine Society guideline targets an IGF-1 SD score between 0 and +2 for treated GH deficiency [11].